SCHEMBL23927435

SCHEMBL23927435

CCOC(=O)c1nnc(Cc2cc(F)cc(Cl)c2)[nH]1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.39
PDE3A Q14432 1/20 0.39
ALOX15 P16050 2/20 0.39
LMNA P02545 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
NTRK1 P04629 1/20 0.37
XPO1 O14980 1/20 0.37
TSHR P16473 1/20 0.37
GPR52 Q9Y2T5 1/20 0.37
ALOX5 P09917 2/20 0.36
KCNH2 Q12809 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
ALPL P05186 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30091704 1.00 PDE3B (0.39) PDE3BPDE3AALOX15LMNAKMT2A
SCHEMBL23927445 0.91 NTRK1 (0.43) LMNAKMT2AALDH1A1MEN1L3MBTL1
SCHEMBL30091457 0.87 TSHR (0.39) LMNAKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL23927479 0.87 TSHR (0.39) LMNAKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL18420957 0.84 ALDH1A1 (0.39) LMNAKMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL30091570 0.83 GPR52 (0.43) NTRK1GPR52DAO
SCHEMBL23927471 0.82 GPR52 (0.39) KMT2AALDH1A1MEN1L3MBTL1MAPT
SCHEMBL30091622 0.82 GPR52 (0.39) KMT2AALDH1A1MEN1L3MBTL1MAPT
SCHEMBL19207821 0.81 PGR (0.39) ALOX15KMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL29415696 0.81 PGR (0.39) ALOX15KMT2AALDH1A1MEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2025-10-07 US disclosed
EP-3901147-B1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2023-11-22 EP disclosed
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-26 US disclosed
CN-113166116-B Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2022-12-27 CN disclosed
EP-3901147-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-10-27 EP disclosed
CN-113166116-A Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2021-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF RIPK1, RIPK3, RIPK4 PDE3B 4066/4885PDE3A 3839/4885ALOX15 1725/4885
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof RIPK1, RIPK3, RIPK4 PDE3B 4066/4885PDE3A 3839/4885ALOX15 1725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.